Home
Search
Search Only:

Search Keyword disease

Total: 48 results found.

Page 1 of 3
... impact on the treatment of multiple sclerosis and other autoimmune diseases, which affect tens of thousands of Canadians. ... Dr. Veillette's team discovered the function of a protein located ...
... to await the results of a clinical trial before making a final decision. He says the province owes it to those with the disease to fully consider the merits of the treatment. Quebec's health minister ...
... pain diseases like multiple sclerosis, and that “it’s time to bring cannabis out from the shadows.” The change in policy is also to allow hospices and specialized ambulances to use certain high-strength ...
... who don't respond to earlier therapy or in patients with aggressive cases of the disease, and is distributed under a strict risk management plan that monitors patients for PML. The risk of the infection ...
Milk could be fortified with vitamin D to strengthen bones and prevent heart disease, cancer & MS. The vitamin is credited with a host of benefits but because the body's stores of it are mainly formed ...
... disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated ...
St. Joseph's Healthcare will start testing whether multiple sclerosis is a vascular disease within two weeks despite European studies questioning the controversial theory. The highly-anticipated study ...
... that it can be used also in diagnosing multiple sclerosis at an earlier stage of the disease than the usual diagnostic tools.... [Read More] Read more: MSRC Latest MS News  ...
... subpopulations in the New York State Multiple Sclerosis Consortium (NYSMSC) database. MSSS is a frequency-rank algorithm relating MS disability to disease duration in a large, untreated reference population. ...
Genentech Inc. is licensing a human monoclonal antibody for autoimmune diseases. Financial terms and other aspects of the deal between the South San Francisco-based unit of Swiss drug maker Roche and NovImmune ...
... Ontario. News reports that Italian doctor Paolo Zamboni last year discovered a treatment for MS that involved unblocking veins have sparked intense interest from people with the disease.... [Read More] ...
Multiple sclerosis is a complex inflammatory disease that is characterized by lesions in the central nervous system.   Both genes and other environmental factors influence disease susceptibility. ...
... multiple sclerosis therapy centre which started in Gibraltar in 2008 helps people with a number of conditions ranging from a scar to motor neurone disease. Multiple Sclerosis is a condition of the central ...
... age range, specific interventions for paediatric MS are lacking. As for rehabilitative strategies, there is some evidence of efficacy in other diseases, in particular brain trauma, tumor, and stroke. ...
... Alumni Auditorium, 395 Lenox Road, Brooklyn, New York 11203. CCSVI is a syndrome in which blood flow from the brain is compromised. While CCSVI is a disease state that by itself often requires intervention, ...
... support was required to walk (time to event (TTE)) was used as a measure of progression rate. The probability of each voxel being 'lesional' was correlated with TTE, adjusting for age, gender, disease ...
... too much on targeted, applied research, mainly drug development, and not enough on non-targeted, basic research into the causes, mechanisms, and prevention of disease. Moreover, drug companies often ...
... from clinical studies, there are papers showing that microbes affect MS," Mazmanian says. "For example, the disease gets worse after viral infections, and bacterial infections cause an increase in MS symptoms." On ...
... for a £6,000 procedure not available in the UK but is said to be able to reverse the symptoms of the paralysing disease. Now two weeks on, the 47-year-old, who has primary progressive MS, says he has ...
... MS (RRMS) patients, as it becomes the world's first oral disease-modifying MS therapy to be granted marketing authorization beating Novartis's Gilenia(fingolimod). Without Tysabri and Extavia launching, ...
«StartPrev123NextEnd»